Recursion Pharmaceuticals, Inc. (NasdaqGS: RXRX)
Health Care · Biotechnology · US
$3.95
-9.52% today · -26.2% 1Y
Recursion Pharmaceuticals, Inc. (NasdaqGS: RXRX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.34B and employs 600 people.
Over the last twelve months the share price has lost 26.2%, trading between 2.77 and 7.18.
Tweenvest scores Recursion Pharmaceuticals, Inc. across four factors: quality 37/100, value 43/100, growth 100/100. Its strongest factor is growth.
RXRX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.34B
- Revenue (TTM)
- $54.86M
- P/E
- —
- EPS
- -1.02
- Dividend yield
- —
- Beta (5Y)
- 1.03
- 52-week high
- $7.18
- 52-week low
- $2.77
- Avg volume (3M)
- —
- Shares outstanding
- 536.27M
- Employees
- 600
- Next earnings
- —
About Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
- ISIN
- US75629V1044
- Founded
- 2013
- Listed since
- Apr 16, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Zealand Pharma A/SCPSE: ZEAL | $2.43B | Dkr234.80 | -1.34% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.38B | $61.20 | -1.39% |
| SELLAS Life Sciences Group, Inc.NasdaqCM: SLS | $2.35B | $11.89 | +2.06% |
| Celldex Therapeutics, Inc.NasdaqCM: CLDX | $2.35B | $29.50 | -1.30% |
| PharmaResearch Co., Ltd.KOSDAQ: A214450 | $2.34B | ₩302,500.00 | -1.14% |
| ADMA Biologics, Inc.NasdaqGM: ADMA | $2.32B | $10.29 | -0.68% |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | $2.32B | $22.06 | -1.32% |
| CanSino Biologics Inc.SEHK: 6185 | $2.27B | HK$35.02 | +1.10% |
Figures last refreshed Oct 11, 2026.